DDInter1796 DDInter1676
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Thioridazine {u} (Compound) resembles {v} (Compound) Prochlorperazine
Thioridazine {u} (Compound) resembles {v} (Compound) Ethopropazine
Thioridazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Thioridazine {u} (Compound) binds {v} (Gene) CYP2D6
Thioridazine {u} (Compound) upregulates {v} (Gene) KDM5B
Thioridazine {u} (Compound) palliates {v} (Disease) schizophrenia
Thioridazine {u} (Compound) is included by {v} (Pharmacologic Class) Phenothiazines
Thioridazine {u} (Compound) downregulates {v} (Gene) VAPB
Thioridazine {u} (Compound) causes {v} (Side Effect) Cholestasis
Thioridazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium oxide
Thioridazine (Compound) resembles Prochlorperazine (Compound)
Thioridazine (Compound) resembles Ethopropazine (Compound)
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine
Thioridazine (Compound) binds CYP2D6 (Gene)
Thioridazine (Compound) upregulates KDM5B (Gene)
Thioridazine (Compound) palliates schizophrenia (Disease)
Thioridazine (Compound) is included by Phenothiazines (Pharmacologic Class)
Thioridazine (Compound) downregulates VAPB (Gene)
Thioridazine (Compound) causes Cholestasis (Side Effect)
Thioridazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide